Researcher from University of Colorado Anschutz Medical Campus Details New Studies and Findings in the Area of Carcinomas (A Phase 1/2 Clinical Trial of Pembrolizumab and Cabozantinib in Metastatic Renal Cell Carcinoma).

According to the news reporters, the research concluded: "Pembrolizumab and cabozantinib treatment in mRCC patients demonstrated encouraging preliminary efficacy and a manageable toxicity profile comparable to other available CPI-TKI combinations." Keywords: Cancer; Carcinomas; Clinical Research; Clinical Trials and Studies; Drugs and Therapies; Health and Medicine; Immunologic Agents; Immunotherapy; Kidney; Monoclonal Antibodies; Nephrology; Oncology; Pembrolizumab Therapy; Pharmaceuticals EN Cancer Carcinomas Clinical Research Clinical Trials and Studies Drugs and Therapies Health and Medicine Immunologic Agents Immunotherapy Kidney Monoclonal Antibodies Nephrology Oncology Pembrolizumab Therapy Pharmaceuticals 1212 1212 1 06/12/23 20230613 NES 230613 2023 JUN 12 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- New research on carcinomas is the subject of a new report. [Extracted from the article]